Seroquel (quetiapine) has a terminal half-life of about 6 hours in adults, meaning plasma concentration drops by half every 6 hours after steady-state levels are reached. This pharmacokinetic property determines dosing intervals and influences how quickly the drug clears from the system.
Half-life measures the time required for a drug's plasma concentration to decrease by 50% during elimination. For seroquel, this value reflects how rapidly the body processes and removes the medication. A 6-hour half-life indicates moderate clearance, requiring twice-daily dosing for most patients to maintain consistent therapeutic levels.
After stopping seroquel, it takes about 30 hours (five half-lives) for the drug to be nearly eliminated from the bloodstream. This timeline affects withdrawal management and risk of rebound symptoms. Individual variation in half-life exists due to age, genetics, and organ function.
Seroquel undergoes extensive hepatic metabolism via cytochrome P450 enzymes, primarily CYP3A4 and CYP2D6. The liver breaks down the drug into inactive metabolites, which are excreted through urine and feces. Because metabolism is rate-limiting, changes in liver function directly impact half-life.
Drug interactions alter seroquel's half-life. Strong CYP3A4 inhibitors like ketoconazole can increase seroquel concentrations by up to 50%, prolonging effective half-life. Conversely, CYP3A4 inducers such as rifampin reduce seroquel levels, potentially lowering efficacy. These interactions require dose adjustments to avoid toxicity or treatment failure.
A 2021 study published in *Clinical Pharmacokinetics* confirmed that seroquel's half-life remains stable across doses from 25 mg to 800 mg daily, indicating linear pharmacokinetics. This predictability supports consistent dosing strategies across therapeutic ranges.
Age, sex, and renal or hepatic impairment affect seroquel clearance. In elderly patients (>65 years), half-life increases to ~8 hours due to reduced metabolic capacity. Dose reductions are recommended in older adults to prevent sedation and orthostatic hypotension.
Patients with moderate to severe hepatic impairment show a 30-50% increase in half-life. The FDA-approved label advises against initiating seroquel in those with severe liver disease. Renal impairment has less impact, as seroquel is primarily metabolized rather than excreted unchanged.
| Factor | Effect on Half-Life | Recommended Action |
|---|---|---|
| Older adults (>65) | Increases to ~8 hours | Reduce dose by 25-50% |
| Severe hepatic impairment | Increases by 30-50% | Contraindicated; avoid use |
| CYP3A4 inhibitors (e.g., ketoconazole) | Increases concentration; prolongs half-life | Monitor for sedation; consider dose reduction |
| CYP3A4 inducers (e.g., rifampin) | Decreases concentration; shortens effective half-life | Consider increasing dose; monitor response |
Genetic polymorphisms in CYP2D6 can also alter seroquel metabolism. Poor metabolizers may experience higher plasma levels and increased side effects, though this effect is less pronounced than with drugs like codeine or tamoxifen.
Many assume seroquel's half-life is longer because it produces lasting effects. However, clinical duration does not equal pharmacokinetic half-life. Seroquel's antipsychotic and mood-stabilizing effects persist beyond 6 hours due to receptor binding affinity and central nervous system distribution, not sustained blood levels.
Another misconception is that stopping seroquel abruptly causes withdrawal. While discontinuation syndrome is rare, abrupt cessation can lead to rebound psychosis or insomnia in some patients. The 6-hour half-life means symptoms may emerge within 12-24 hours after last dose, especially in long-term users.
A 2019 review in *Journal of Clinical Psychiatry* noted that seroquel's half-life is shorter than many antipsychotics like olanzapine (21 hours) or risperidone (3 hours), placing it in a middle range. This makes it suitable for twice-daily dosing and allows faster titration compared to longer-half-life agents.
A 42-year-old woman with bipolar I disorder was prescribed seroquel 300 mg twice daily for mood stabilization. After six months, she reported drowsiness and weight gain. Her psychiatrist ordered a trough level test, which showed 1.8 μg/mL-within the therapeutic range (1-3 μg/mL).
Given her symptoms, the team adjusted the timing to morning and evening doses to reduce peak sedation. They also evaluated her liver function, which was normal. No drug interactions were detected. The decision to maintain the dose was based on the understanding that seroquel's 6-hour half-life allows predictable plasma profiles with twice-daily administration.
When tapering off seroquel later, the dose was reduced by 50 mg every 3 days over 4 weeks. This slow reduction prevented rebound mania, consistent with guidelines from the American Psychiatric Association.
The 6-hour half-life of seroquel governs its dosing schedule, elimination timeline, and interaction profile. Understanding this helps clinicians tailor therapy and anticipate patient responses. Always consider individual factors like age, organ function, and concomitant medications when managing seroquel therapy.